Blasto or Histo? Your Dog's Antigen Test May Not Tell
A positive Blastomyces or Histoplasma antigen test may not identify your dog's infection. Learn what cross-reactivity means and what to ask your veterinarian next.
Usually, a positive Blastomyces or Histoplasma antigen test cannot tell the two infections apart in a dog. The assays react to similar fungal material, so the name printed on the report does not necessarily identify the organism. A positive can support fungal infection when it fits the dog's illness, but false positives also occur. Your veterinarian must interpret the result with the examination, history and other findings. MiraVista diagnostic guidance; Canine collection study.
The useful next question is what remains uncertain: whether the result reflects infection, which fungus is involved, or how to follow a confirmed infection over time. Those questions can require different tests. This guide focuses on dogs and the named Blastomyces and Histoplasma antigen EIAs, or enzyme immunoassays. It does not provide a diagnosis from an individual result.
What a Positive Result Can and Cannot Establish
Blastomyces and Histoplasma antigen assays detect fungal cell-wall material called galactomannan. Cross-reactivity means material from one fungus can trigger an assay named for the other. It is different from contamination: in a cross-reacting result, a real fungal infection may be present even though the report's organism name is misleading. Merck Veterinary Manual specifically warns that the urine antigen assay for blastomycosis can cross-react with Histoplasma. Merck diagnosis overview.
MiraVista reports nearly complete, 99% cross-reactivity between the two antigen tests, with discrepancies mainly at low positive levels. This is the manufacturer's summary, not a new independent estimate in dogs. It does not mean your dog has a 99% chance of infection, nor that blasto and histo are equally likely. The animal's history and clinical findings still matter. MiraVista cross-reactivity explanation.
A separate human serum study helps explain the overlap. Granger and colleagues reported 94.7% positive agreement, 72 of 76, and 99.3% overall agreement, 3,506 of 3,529, between the paired assays. Overall agreement includes the many samples negative on both. These are human laboratory agreement figures, not canine sensitivity or diagnostic certainty. The study appeared online in December 2023 in the January 2024 journal collection. Granger human serum study.
For an owner reading a portal message, separate the laboratory finding from the veterinarian's conclusion. Write down the exact result first, then ask what evidence connects it to the suspected disease. If the clinician has already identified an organism in tissue, the same antigen report has a different role: it may help establish a baseline for follow-up rather than settle the organism's identity.
Would Ordering the Other Antigen Test Help?
MiraVista advises that testing both antigens is unnecessary in areas where both infections occur because they cross-react and treatment and monitoring are similar. That is a reasonable reason to avoid a redundant test. Similar treatment does not mean every dog receives an identical plan, or that organism identification never matters. Ask what a proposed additional test would change. MiraVista ordering guidance.
| Proposed next step | Question it addresses | What to clarify with the veterinarian |
|---|---|---|
| The other fungal antigen assay | Would another assay detect the overlapping antigen signal? | How would this result add information beyond the first antigen test? |
| Antibody testing | Does the dog have a detectable immune response that helps interpret the antigen finding? | Which antibody method is intended, and what would a positive or negative add? |
| Cytology or tissue examination | Can organisms be identified in a relevant sample? | Is there an appropriate site to sample, and what would an inconclusive result mean? |
| Repeat testing after reviewing collection | Is an unexpected finding reproducible in a suitable specimen? | Which specimen and collection approach does the veterinary team recommend? |
These are questions for a visit, not a menu to order independently. A family may reasonably ask why another test is needed even when the first is positive. The answer should identify the uncertainty being resolved. Request that explanation in the written plan, especially if a primary veterinarian and specialist are sharing care.
Why Collection Matters for an Unexpected Positive
Como and colleagues prospectively studied 60 dogs: 30 suspected of histoplasmosis and 30 healthy controls. They compared free-catch urine, cystocentesis urine collected from the bladder, and a portion of cystocentesis urine deliberately exposed to a hospital surface. Only three dogs were ultimately diagnosed with histoplasmosis. The reported false-positive counts used the other 57 dogs as the denominator. Como 2026 study.
| Collection or grouping | Dogs with a false-positive result | Rounded rate reported in the abstract |
|---|---|---|
| Cystocentesis | 2 of 57 | 4% |
| Free catch | 4 of 57 | 7% |
| Hospital-contaminated sample | 6 of 57 | 11% |
| At least one positive across methods | 9 of 57 | 16% |
The rows overlap because each dog contributed samples collected in different ways. They must not be added together. The 16% is a dog-level finding across methods, not the rate for one routine specimen. Six of the 30 healthy controls had at least one positive. The study used clinical diagnosis as its reference standard, and the small population limits generalization. Study results and limitations.
The practical implication is to discuss an unexpected or low positive from a nonsterile specimen with the veterinarian, including whether cystocentesis confirmation is appropriate. The study does not establish the odds that your dog's positive is wrong, prove a particular environmental organism caused it, or make cystocentesis error-free. The veterinarian decides which collection approach suits the patient. Study clinical relevance.
Keep the original report when a repeat sample is requested. On your record, distinguish the date the sample was collected from the date the result arrived. Ask the clinic to supply the collection method if it is missing; an empty field is better than a guess. If two reports disagree, bring both rather than summarizing them as one positive and one negative.
A Negative Test May Leave a Diagnostic Question Open
In Spector and colleagues' 2008 study of 46 dogs with confirmed blastomycosis, antigen sensitivity was 93.5% in urine and 87.0% in serum. Antibody sensitivity was 76.1% by EIA and 17.4% by agar gel immunodiffusion. These historical figures describe that study's patients and methods; they are not one performance estimate for all present-day fungal tests. Spector canine study.
MiraVista notes that antigen can be negative in mild or localized disease, and that serum testing or antibody testing may add information when suspicion persists. A negative urine result therefore does not necessarily end the workup. Conversely, the existence of false negatives is not a reason to assume every unexplained illness is fungal. MiraVista interpretation guidance.
Ask the veterinarian to explain the next decision in plain language: what finding would make fungal infection more or less likely, which test addresses it, and when the plan will be reviewed. Keep that explanation beside the report. It is more useful than comparing a single laboratory number with a percentage quoted from an unrelated population.
How the Veterinarian Can Identify the Fungus
Merck describes identifying characteristic thick-walled, broad-based budding yeasts in affected tissue or fluid as a way to diagnose blastomycosis. The veterinarian chooses whether and where to sample. Antigen testing and looking for organisms answer different questions; an antigen result cannot replace an organism identification already available from pathology. Merck diagnostic methods.
Antibody testing can also contribute, with limits. In MiraVista's review of 518 dogs tested from 2017 through February 2020, 184 had at least one positive antigen or antibody result. Of those 184, 46, or 25%, were antibody positive and antigen negative. That is not proof that antibody testing rescued 25% of all infected dogs: this was a selected laboratory series, and the report calls these potentially positive cases. The manufacturer says a higher paired IgG concentration may suggest the organism when both antibodies are detected, while calling for further confirmation studies. MiraVista antibody review.
For the appointment, ask whether the proposed test provides direct organism identification or a supportive clue. If the answer is a clue, ask what evidence will be considered alongside it. This helps avoid replacing overconfidence in one antigen test with overconfidence in one antibody result.
An Unusual Case Shows Why the Report Name Is Not Enough
A 2025 report by Kyle L. Granger Jr. and colleagues describes a dog with pneumonia and prior travel to Utah and Idaho. Its Histoplasma urine antigen was positive at 11.33 ng/mL, but culture and sequencing identified Blastomyces helicus. This was cross-reactivity in a confirmed fungal infection, not proof that the positive signal was meaningless. It also shows that misidentification is not confined to tiny positive values. Blastomyces helicus case report.
Both antigen assays declined during that dog's treatment and were negative at six months. One case cannot establish assay interchangeability or predict another dog's course. Its useful lesson for owners is to give the veterinarian a complete travel history and avoid treating the assay name as a final identification. Specialist laboratory testing may be appropriate when the presentation is unusual; culture handling belongs with the veterinary team and laboratory. Case findings and limitations.
Keep Monitoring Consistent With the Veterinary Plan
MiraVista recommends continuing the antigen test that was positive at baseline, generally at three-month intervals during treatment and at six and twelve months after stopping. These are published follow-up suggestions, not a fixed schedule for every dog. Record the assay, laboratory and specimen, and have the veterinarian explain any change. Do not treat urine and serum values or different assays as one interchangeable numerical series. MiraVista follow-up guidance.
Merck recommends continuing blastomycosis treatment until two negative antigen results three to four weeks apart, while also assessing whether active disease remains; it notes radiographic changes may take much longer to resolve. This is guidance for the treating clinician, not an owner-operated stopping rule. A declining result supports follow-up assessment but does not independently prove cure, correct dosing or medication adherence. Merck treatment assessment.
When a recheck is booked, ask what information should come back with the result. A useful written response states how the veterinarian interprets the trend, whether any uncertainty remains, and the next appointment or contact plan. Keep the instruction itself, not just the value. If the report arrives before the clinic's interpretation, ask for that interpretation before making medication decisions.
The Worksheet: Record the Assay, Specimen and Follow-Up Plan
Use this worksheet to prepare for the veterinary discussion. It is an editorial record-keeping aid, not a validated diagnostic score. Copy information from the original report and ask the clinic to complete missing details. The final column is deliberately a question rather than an instruction: it makes clear which decisions still need the veterinarian's answer.
| Field | What to record | Question for the veterinary team |
|---|---|---|
| Test identity | The full antigen assay name exactly as printed; keep the complete report. | Does this report name the organism or the assay that was ordered? |
| Performing laboratory | The laboratory that actually performed the assay, if different from the submitting clinic. | Which laboratory and assay should we use for the next measurement? |
| Specimen | Urine or serum; note if there are separate reports for both. | Which result is being used as our baseline, and why? |
| Collection method | The clinic-confirmed method, such as cystocentesis or free catch; record unknown if necessary. | Does collection affect how you interpret this particular finding? |
| Timing | The sample date, report date and relevant treatment stage supplied by the clinic. | Which date should we use when arranging the next check? |
| Result wording | The exact value, units, positive or negative wording, and any above- or below-quantification flag. | Is a number directly comparable with the earlier result, or does the reporting limit matter? |
| Supporting evidence | The veterinarian's explanation of examination, imaging, cytology, pathology or other relevant findings. | What supports the working diagnosis beyond the antigen result? |
| Antibody findings | Any antibody test name, method and result, recorded separately from antigen findings. | Does this add a clue, and what are its limitations in our dog? |
| Identification still needed | The uncertainty the veterinarian is trying to resolve and any confirmation discussed. | Would another test change care, interpretation or referral? |
| Monitoring agreement | The assay selected, next appointment date and who will communicate results. | What should we do if the report arrives before we hear your interpretation? |
| Travel and shared records | Relevant locations and dates, plus which clinics already have the reports. | Does the history change which organisms or tests you are considering? |
For a first positive result, start with the test identity, specimen and supporting-evidence rows. Bring the original report to the appointment and ask the veterinarian to separate what is established from what remains a working diagnosis. Write the answer in the clinic's terms; do not rewrite a suspected infection as a confirmed species simply to make the record shorter.
For a discordant repeat, place the reports side by side and complete one worksheet entry for each sample. Check whether the specimen, method or laboratory differs before asking how the results fit together. Do not average the numbers or select the one that seems more reassuring. Record the clinician's reconciliation and the agreed next step so another clinic can follow the reasoning.
For monitoring, take the previous report and the last written plan to each appointment. Ask the team which new result belongs in the same series and annotate any intentional change. If care moves to a specialist, request that the complete reports accompany the referral. A short portal summary can omit the collection method, units or reporting flags that the next veterinarian needs.
Where the Evidence Stops
MiraVista manufactures the assays discussed here. Its FAQ and 518-dog review are manufacturer materials. The 2026 collection study was funded by MiraVista, and coauthor Andrew S. Hanzlicek was employed by the company; the paper discloses both. Its small number of diagnosed infections and reliance on clinical classification limit how confidently its estimates transfer to other populations. Study disclosures.
The evidence also spans different years, populations and methods. The 2008 canine study is historical; the large agreement series concerns human serum; and the helicus example is one dog. Their percentages should not be pooled into a single accuracy claim. None establishes the meaning of an individual dog's result without clinical interpretation. This guide does not extend those findings to cats or provide a universal geographic or treatment rule.
